CD28 co-stimulation in T-cell homeostasis: a recent perspective

Niklas Beyersdorf
Thomas Kerkau
Thomas Hünig
Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany

Abstract: T-cells play a key role within the adaptive immune system mediating cellular immunity and orchestrating the immune response as a whole. Their activation requires not only recognition of antigen/major histocompatibility complexes by the T-cell receptor but in addition co-stimulation via the CD28 molecule through binding to CD80, CD86, or as recently discovered, inducible co-stimulator ligand expressed by antigen-presenting cells. Apart from tight control of the co-stimulatory signal by the T-cell receptor complex, expression of the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) sharing its ligands with CD28 is required to avoid inappropriate or prolonged T-cell activation. CD4+ Foxp3+ regulatory T (Treg) cells, which are crucial inhibitors of autoimmunity, add another level of complexity in that they differ from conventional non-regulatory CD4+ T-cells by strongly depending on CD28 signaling for their generation and homeostasis. Moreover, CTLA-4 is constitutively expressed by Treg cells where it serves as a key mediator of suppression, while conventional CD4+ T-cells express CTLA-4 only after activation. Here, we discuss recent insights into the molecular events underlying CD28-mediated co-stimulation, its impact on gene regulation, and the differential role of CD28 expression on Treg cells versus conventional CD4+ and CD8+ T-cells. Moreover, we summarize the exciting therapeutic options which have arisen from our current understanding of T-cell co-stimulation. Some of these have already been translated into the clinic, while others are expected to follow soon due to promising preclinical results. In particular, we discuss the failed 2006 trial of the CD28 superagonist TGN1412, and the return of this potent T-cell activator to clinical development.

Keywords: CTLA-4, mAbs, rheumatoid arthritis, Treg cells, CD28 superagonist, TGN1412

Introduction: T-cell responses and the role of CD28 co-stimulation

CD28 is a homodimeric stimulatory cell surface receptor of the Ig superfamily. It is expressed on virtually all T-cells in rodents, and on the vast majority of CD4+ but only about half of circulating human CD8+ T-cells. The control of T-cell responses by CD28 co-stimulation provides a means of preventing unwanted (anti-self) and triggering wanted (antimicrobial) immunity. Thus, antigen-presenting cells (APCs), in particular dendritic cells, are not only uniquely able to capture, transport, and (cross-)present microbial antigens but are also equipped with pattern recognition receptors that provide information about the captured antigen. If this is an infectious agent, CD80 and CD86, the ligands for CD28, the main co-stimulator of primary T-cell responses, are upregulated (Figure 1). If T-cells inspecting the surface of dendritic cells in lymphoid tissues detect major histocompatibility complex molecules loaded with cognate pep-
tide and simultaneously engage CD80/86 with CD28, they are fully activated to proliferate, and under the guidance of additional, cytokine-mediated signals, differentiate into the various types of effector cells; without co-stimulation, they become refractory to further stimulation (a situation called anergy) or even undergo apoptosis. CD28 engagement alone, on the other hand, is without apparent consequence for the T-cells. As we shall see, however, very strong CD28 signals can synergize with the weak tonic signals generated by the process of antigen search itself to trigger T-cell activation. Compared to other, activation-induced, molecules with co-stimulatory properties such as CD27, OX40, and 4-1BB, CD28’s constitutive expression even on resting T-cells explains its central and prominent role in T-cell activation.

The power of co-stimulated T-cell responses, and the potential damage they can do if misguided, warrants effective control. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) (CD152), which is constitutively expressed on regulatory T (Treg) cells and upregulated on conventional T-cells after activation, is one key element providing this control (Figure 1). This is illustrated by the catastrophic autoimmune-lymphoproliferative disease experienced by CTLA-4-deficient mice and by autoimmunity observed in cancer patients undergoing CTLA-4 blockade. The intimate interrelation of CD28-mediated co-stimulation and CTLA-4-mediated inhibition is apparent not only from their use of the same ligands, for which they compete at the surface of APCs (Figure 1), but also from the absence of autoimmunity in mice lacking both, CD28 and CTLA-4.

Here, we briefly review the structural and functional interactions of CD28, CTLA-4, and their shared ligands, and describe established and emerging therapeutic approaches that manipulate the stimulatory and inhibitory components of this system to either suppress unwanted immunopathology or boost immunity to self- or near-self-antigens, which can be targeted for T-cell-mediated attack on tumor cells.

### Molecular mechanisms and signaling pathways

As already mentioned, CD28 induces a co-stimulatory signal in T-cells recognizing cognate antigen-major histocompatibility complexes via their T-cell receptor (TCR). In fact, there are at least three mechanisms to ensure that CD28 is only capable of generating a co-stimulatory signal when the TCR is engaged but does not activate the T-cell by itself.

The first mechanism concerns the binding of CD28 to its ligands CD80 and CD86 on the surface of the APCs. TCR ligation has only recently been shown to induce a conformational change in the CD28 molecule (Figure 2B). It was further shown by the same group that this conformational change within the CD28 homodimer allows for bivalent enhanced avidity binding to CD80. Without TCR stimulation, CD28 is only capable of binding monovalently, that is, with low affinity (Figure 2A). For the inhibitory receptor CTLA-4, a close structural relative of CD28, bivalent binding has been recognized much earlier than for CD28 (Figure 2C). Accordingly, it was assumed that the high avidity of CTLA-4 for the shared ligands would explain why CTLA-4-mediated inhibition dominates over CD28-induced co-stimulation (reviewed in Walker and Sansom). How the avidity of CD28 after the activation-induced conformational changes compares to that of CTLA-4 has, however, not yet been addressed. It may, however, be speculated that it is still below that of CTLA-4 as monovalent binding of CTLA-4 is of higher affinity than monovalent binding of CD28.

The second mechanism is the strict dependence of even supraphysiological CD28-derived signals, as those induced by superagonistic anti-CD28 monoclonal antibodies (mAbs) (CD28 superagonist [CD28SA], see The power of CD28SAs section), on the provision of at least a “tonic” signal from the TCR (Figure 2A and B). This means that there are signaling molecules in the T-cells like the zeta-associated protein of 70 kDa (ZAP-70) which are stimulated by the TCR complex but not by CD28 and which control the activation status of the SH2 domain-containing leukocyte protein of 76 kDa (SLP76)/VAV1/interleukin-2-inducible T-cell kinase (ITK) signalosome integrating the TCR and CD28 signaling pathways (Figure 3).

Third, ligation of CD28 in the absence of TCR stimulation may lead to the induction of inhibitory signals in the T-cell (Figure 2A). This is exemplified by the induction of...
Co-stimulation control of T-cell homeostasis

Acid sphingomyelinase activity upon CD28 ligation in the absence of TCR stimulation,\textsuperscript{10,11} which leads to the generation of ceramide from sphingomyelin. Accumulation of ceramide in the cell membrane is, in turn, associated with inhibition of the T-cell.\textsuperscript{12,13} At least under the in vitro conditions tested so far using mAbs, the induction of this inhibitory signal is prevented upon simultaneous stimulation of the TCR together with CD28, thus allowing for full T-cell activation.\textsuperscript{11} This very interesting observation, however, still awaits confirmation in assays studying natural CD28–ligand interactions.

Upon TCR and CD28 stimulation, the T-cell forms an immunological synapse (IS) with the APC (reviewed in Kumari et al\textsuperscript{14} and Saito et al\textsuperscript{15}). The IS consists of distinct supramolecular activation clusters (SMACs) arranged like a bull’s eye with TCR complexes and CD28 in the center (cSMAC) and molecules like lymphocyte function-associated antigen-1 or CD45 in the peripheral or distal SMAC (pSMAC/dSMAC). The CD28 molecules within the SMAC transduce activating signals into the cell via the YNMN and the PYAP motifs contained in the intracellular part of CD28 (reviewed in Chen and Flies\textsuperscript{1} and Boomer and Green\textsuperscript{16}) (Figure 3). As a consequence, phosphoinositide 3-kinase (PI3K), protein kinase C, growth factor receptor-bound protein 2, RAS guanyl nucleotide-releasing protein, and lymphocyte cell-specific

**Figure 2** Scheme of the molecular mechanisms underlying CD28-mediated co-stimulation and CTLA-4-mediated inhibition.

**Notes:** (A) In resting T-cells, the lack of an agonistic TCR complex-derived signal together with the suggested propensity of isolated CD28 stimulation to induce inhibitory signaling in the T-cells prevents activation. (B) Upon antigen recognition, CD28 undergoes a conformational change allowing for efficient ligand binding and TCR signal amplification. (C) CTLA-4 counteracts CD28-mediated co-stimulation both intracellularly, that is, in cis, and extracellularly in trans by ligand transendocytosis and activation of immunosuppressive genes in APCs.

**Abbreviations:** CTLA-4, cytotoxic T-lymphocyte antigen-4; TCR, T-cell receptor; APCs, antigen-presenting cells; MHC, major histocompatibility complex.
A and SH2 domain-containing γ Newsletter.

Like ZAP-70 and the linker of activated T-cells (reviewed in chains of the TCR complex and recruit signaling molecules via its cytoplasmic tail, efficiently recruits phosphatases to the IS (Beyersdorf et al). As a result, CTLA-4 is also very efficiently recruited from intracellular vesicles to the IS, which is distinct from the signal induced in the T-cell upon co-ligation as the interaction of CD80/CD86 and CD28, a very similar, if not identical, co-stimulatory signal upon B7-H2-inducible co-stimulator interaction. As a consequence of these dephosphorylation events and/or due to molecular pathways yet to be discovered, CTLA-4 counteracts the formation of lipid microdomains, the so-called lipid rafts, induced upon TCR and CD28-mediated co-stimulation which are required for efficient protein clustering (reviewed in Chen and Flies, Rudd, and Rudd et al). As a result, CTLA-4 ligation inhibits the formation of the so-called ZAP-70 microclusters at the cell membrane, again interfering with proximal TCR signaling. Beyond interfering with the signaling process itself, CTLA-4 prevents the induction of the integrin-mediated “stop signal” in T-cells upon contact with APCs. This “stop signal” contributes to the formation of a stable IS, is induced by TCR ligation, and probably amplified by CD28 co-ligation.

Due to its capacity to block CD80 and CD86, to transmit immunosuppressive signals into APCs via these ligands, and even capture them from the surface of APCs by transendocytosis (reviewed in Walker and Sansom), CTLA-4 is also a potent inhibitor of T-cell activation in trans. In bone marrow chimeric mice, it has been shown that CTLA-4 expression by Treg cells is necessary and sufficient to prevent the catastrophic lymphoproliferative syndrome induced by CTLA-4 knockout T-cells. Together with evidence from studies on T-cell responses toward foreign antigens, it appears that the key function of CTLA-4 in vivo is to mediate suppression by Treg cells in trans. Modulation of immune responses by Treg cells through CTLA-4, however, does not necessarily compromise immunity but may even be crucial for the development of efficient memory responses requiring the so-called multifunctional effector CD4+ T-cells.

Apart from CD80 and CD86, the inducible co-stimulator ligand, B7-H2, has recently been identified to also bind to CD28 and CTLA-4 expressed by human T-cells. Functionally, binding of B7-H2 to CD28 appears to induce a very similar, if not identical, co-stimulatory signal upon TCR co-ligation as the interaction of CD80/CD86 and CD28, which is distinct from the signal induced in the T-cell upon B7-H2-inducible co-stimulator interaction.

In summary, CD28 induces a co-stimulatory signal in the T-cell upon co-ligation together with the TCR, thus amplifying the TCR complex-derived signal and by recruiting additional signaling molecules. The negative regulator CTLA-4 counteracts CD28 signaling in cis by recruiting inhibitory phosphatases to the IS, and in trans by transmitting inhibitory signals into APCs, as well as by competing for the binding and removal of co-stimulatory ligands.
CD28 co-stimulation: gene regulation and biological effects

In-depth gene expression analysis demonstrated that CD28 co-stimulation modulates TCR-induced gene expression rather than regulating a distinct cluster of genes. Within the scope of this review, we focus on the impact of CD28 co-stimulation on the expression of genes that are involved in T-cell proliferation, differentiation, and survival.

Following TCR/CD28 stimulation, resting T-cells enter into the cell cycle on the one hand by activation of cyclin D2 and CDK4/6 complexes mediating progression into the G1 phase. On the other hand, CD28 signaling antagonizes the effects of CDK inhibitors like INK4C that negatively control G0/G1 transition. T-cell proliferation is sustained by production of interleukin-2 (IL-2) that acts in an autocrine fashion (Figure 4A). The role of CD28 co-stimulation in the induction of IL-2 gene expression has been extensively studied. CD28 has been shown to upregulate the activity of several transcription factors including nuclear factor of activated T-cells (NFAT), nuclear factor-κ-light-chain enhancer of activated B cells (NF-κB), and activator protein-1 (AP-1). Activation of IL-2 transcription is initiated by binding of these transcription factors to specific regions in the IL-2 promoter: the CD28 responsive element and the adjacent NF-IL-2B AP-1 site. Besides transcriptional control of the IL-2 gene, CD28 signals have been shown to enhance the stability of the IL-2 mRNA. IL-2 exerts its function on T-cells by binding to the high-affinity trimeric IL-2 receptor (IL-2R) composed of CD122 (IL-2Rβ), CD132 (the common cytokine receptor γ-chain) and CD25 (IL-2Rα) (Figure 4A). CD25 gene expression in T-cells is rapidly induced upon TCR/CD28 co-stimulation by activation of NF-κB, NFAT, AP-1, and cAMP response element-binding protein/activating transcription factor (reviewed in Kim et al.). Thereupon, IL-2 binds to the high-affinity receptor leading to further enhancement of CD25 expression by a Stat5-dependent mechanism. Taken together, CD28 co-stimulation affects T-cell activation and proliferation at multiple levels, including amplification of signals in response to antigen recognition, activation/translocation of transcription factors promoting expression of proteins required for cell-cycle entry, and of the growth-promoting cytokine IL-2 along with its high-affinity receptor.

CD28 co-stimulation is not only a booster of T-cell proliferation and cytokine production but in addition influences the survival of T-cells. Apoptosis in T-cells is mediated by two major pathways: I) The extrinsic pathway is initiated by binding of a ligand to a death receptor (eg, Fas) expressed on the cell surface leading to the activation of the caspase cascade. II) The intrinsic apoptotic pathway is activated by several stress stimuli like DNA damage or growth factor withdrawal and leads to mitochondrial outer membrane permeabilization and release of proapoptotic factors. It has been shown that interactions between CD28 and CD80/86 result in the intracellular accumulation of the anti-apoptotic protein.

**Figure 4** Schematic modes of action of drugs targeting CD28 and/or CTLA-4.

**Notes:** (A) In the absence of pharmaceutical intervention, both Tconv and Treg cells may receive a co-stimulatory signal, and CTLA-4 is capable of mediating ligand transendocytosis. (B) While CTLA-4-Ig blocks both interactions, (C) conventional and (D) ligand-blocking anti-CD28 mAb/SCFV only inhibit co-stimulation without interfering with the action of CTLA-4. (E) Anti-CTLA-4 mAbs inhibit CTLA-4 on Tconv and Treg cells and deplete Treg cells, thus enhancing T-cell responses. (F) CD28SAs differ from the other reagents in that they induce a strong agonistic signal in Tconv and Treg cells, but the Treg cells quickly inhibit the Tconv cells including pathogenic autoreactive T-cells. At low doses, activation is largely restricted to Treg cells because their autoreactivity provides more signaling substrate for amplification.

**Abbreviations:** CTLA-4, cytotoxic T-lymphocyte antigen-4; Tconv, conventional T-cells; Treg, regulatory T-cells; CTLA-4-Ig, CTLA-4 linked to the Fc domain of human IgG1; mAb, monoclonal antibody; SCFV, single-chain Fv; CD28SA, CD28 superagonist; IL-2, interleukin-2; TCR, T-cell receptor; MHC, major histocompatibility complex; APC, antigen-presenting cell.
Impact of CD28 ligation on different mouse T-cell subsets on their activation and differentiation

<table>
<thead>
<tr>
<th>Subset</th>
<th>Survival in steady state</th>
<th>Activation during immune response</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conventional</td>
<td>–</td>
<td>+++</td>
<td>1</td>
</tr>
<tr>
<td>CD4+ T-cells</td>
<td>–</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>CD4+ Treg cells</td>
<td>+++</td>
<td>–</td>
<td>55–57,72,73</td>
</tr>
<tr>
<td>CD8+ T-cells</td>
<td>–</td>
<td>+</td>
<td>102,103</td>
</tr>
</tbody>
</table>

Notes: –, no impact; +, mildly enhanced; +++, strongly enhanced by CD28 co-stimulation.

Abbreviation: Treg, regulatory T-cells.
ing growth factor beta and IL-2 (induced Treg [iTreg] cells). In T-cells from conventional CD28 knockout mice, iTreg induction by anti-CD3 plus transforming growth factor beta is defective but can be restored by adding IL-2. However, since CD4+ T-cells in such mice are adapted to CD28 deficiency, the conclusion that the observed CD28 dependence of this differentiation process is fully explained by the requirement for CD28 co-stimulation in the production of IL-2 by conventional CD4+ T-cells is shaky. For a definitive answer, in vivo experiments using induced CD28 deletion in mixed bone marrow chimeras where wild type and inducibly CD28-deleting T-cells coexist and can be identified, along with a physiological TCR stimulus will be required.

Taken together, CD28 is a key player not only in the activation of T-cell effector responses but also in their control by Treg cells, which recognize self-antigens in a co-stimulation-dependent manner, and sense ongoing effector T-cell responses via the CD28-dependent production of IL-2.

**Targeting CD28 co-stimulatory pathways**

**Inhibition of CD28-mediated co-stimulation**

**CTLA-4 linked to the Fc domain of human IgG1**

As described above, CTLA-4 binding to CD80 or CD86 inhibits T-cell activation and proliferation. Linsley et al exploited this property of CTLA-4 to generate a fusion protein consisting of the extracellular domain of human CTLA-4 linked to the Fc domain of human IgG1 (CTLA-4-Ig; Abatacept) (Figure 4B). Ig Fc domains of such fusion proteins are helpful for several reasons as they not only facilitate purification and detection but also markedly increase the in vivo half-life of such recombinant proteins. Further studies showed that Abatacept – similar to CTLA-4 itself – has a high affinity for CD80 and CD86, blocks CD28-dependent co-stimulation, and inhibits T-cell proliferation in vitro (reviewed in Linsley and Nadler65) (Figure 4B). Based on these results, CTLA-4-Ig was successfully tested in numerous preclinical animal models of autoimmune diseases. For example, application of CTLA-4-Ig in collagen-induced arthritis of the rat prevented the onset of the disease indicating that CTLA-4-Ig-mediated blockade of T-cell co-stimulation in vivo inhibits the activation of autoreactive T-cells in the collagen-immunized animals.

Likewise, autoreactive T-cells play an important role in the immune pathology of many human autoimmune diseases including RA, and thus, their co-stimulation-dependent activation presents a potential target of CTLA-4-Ig. Indeed, several clinical trials demonstrated safety and efficacy of Abatacept in RA, leading to the approval of this drug in the US in 2006 for the treatment of moderate-to-severe RA, and in 2008 for the treatment of juvenile idiopathic arthritis. In contrast, Abatacept failed to protect graft survival in an animal model of renal transplantation due to incomplete blockade of T-cell activation. In order to overcome this deficit, a second-generation CTLA-Ig protein – Belatacept – was generated, which differs from Abatacept in two amino acids resulting in tenfold higher in vitro potency. After promising results in nonhuman primate models of renal transplantation, Belatacept was successfully tested in Phase II and III clinical trials and approved in 2011 by the US Food and Drug Administration for rejection prophylaxis in adult kidney transplant recipients (reviewed in Wojcichowski and Vincent).

**Blocking CD28 with mAbs and recombinant single-chain Fv fragments**

Apart from inhibiting CD28-mediated co-stimulation, CTLA-4-Ig also abrogates the interaction of CTLA-4 on T-cells with its ligands expressed by APCs (Figure 4B). Therefore, CTLA-4-Ig also prevents negative signaling into the T-cell or the APC, which diminishes the effect of the CD28 blockade achieved by this reagent.

A solution to this dilemma is to interrupt the interaction of CD28 with its ligands by directly targeting the CD28 molecule. Seemingly paradoxically, CD28-specific mAbs, which in vitro are capable of inducing a potent co-stimulatory signal in T-cells inhibit unwanted T-cell responses in vivo (Figure 4C). However, in the absence of TCR ligation, the signal induced by these anti-CD28 mAbs is not suitable to activate the T-cell but rather results in complete down-modulation of CD28 expression at the cell surface (Figure 4C). Upon subsequent encounter of antigen, the T-cell is functionally CD28 deficient and will, thus, not receive an adequate co-stimulatory signal. Apart from down-modulating CD28 expression at the cell surface, conventional anti-CD28 mAbs may also protect from immunopathology, particularly acute graft-versus-host disease, by increasing interferon-γ expression, which in turn increases apoptosis in alloreactive pathogenic T-cells. As already mentioned, induction of acid sphingomyelinase activity by anti-CD28 mAbs also inhibits subsequent T-cell activation.

The most straightforward way to inhibit CD28 signaling is to generate CD28-specific mAbs that block the interaction of CD28 with its ligands (Figure 4D). For the mouse, mAb E18, itself raised in CD28-deficient mice, was the first mouse-anti-mouse CD28 mAb capable of fully inhibiting ligand binding to CD28. Despite its capacity to strongly
co-stimulate T-cells in vitro, application of E18 as an intact antibody blocked CD28 stimulation upon injection into healthy mice in vivo leading to a gradual depletion of Treg cells due to their strong dependence on CD28 signaling for survival. Under conditions of pathological T-cell activation such as during a superantigen response or during acute graft-versus-host disease, this is different, however. Here, pathogenic conventional CD4+ T-cells are more dependent on CD28-mediated co-stimulation for their activation and expansion than Treg cells. Therefore, under these inflammatory conditions, application of mAb E18 inhibited the expansion of the pathogenic T-cells more strongly than that of Treg cells leading to an increase in Treg cell frequencies among CD4+ T-cells. This shift in the balance between the Treg cells and the pathogenic T-cells crucially contributed to the suppression of the pathogenic T-cell response.

To definitely avoid the generation of an agonistic signal, it is, however, necessary to derive monovalent reagents that block ligand binding, either in the form of Fab fragments derived by enzymatic cleavage or as genetically engineered single-chain Fv (SCFV) fragments, derived from ligand-binding site-directed mAbs (Figure 4D). Fab fragments of mAb E18 similarly inhibited expansion of pathogenic T-cells as did the intact antibody, and an SCFV derived from another anti-CD28 mAb, clone PV-1, also suppressed pathogenic T-cell responses in mice and concomitantly increased the frequencies of Treg cells among CD4+ T-cells. In this study, the benefits of intact CTLA-4 signaling upon CD28 blockade were revealed as inhibiting CTLA-4 signaling also reverted the protective effect of the anti-CD28 SCFV.

For clinical use, a pegylated anti-CD28 SCFV named FR104, which was derived from the anti-CD28 mAb clone CD28.3, is in development. This reagent has already been shown to prevent graft rejection in monkeys and to inhibit the induction of xenogenic graft-versus-host disease by human T-cells transplanted into NOD SCID mice. The pegylated anti-CD28 SCFV also depended on intact CTLA-4 signaling to be efficient.

Taken together, selective blockade of CD28–ligand interaction has been shown to allow for CTLA-4-dependent suppression of pathologic immune responses in preclinical animal models. The basis for further development of FR104 to inhibit CD28-mediated co-stimulation in patients.

### Boosting CD28-mediated co-stimulation

<table>
<thead>
<tr>
<th>CTLA-4 blockade</th>
</tr>
</thead>
</table>
| The function of CTLA-4 as a negative regulator of adaptive immune responses led to the hypothesis that CTLA-4 blockade might liberate CD80/86 for interaction with CD28 and promote increased T-cell activation and proliferation (Figure 4E). Thus, it was thought that blockade of this immune checkpoint might break immunological tolerance to malignant T-cells and lead to enhanced T-cell-mediated rejection of tumors. Indeed, seminal work by Leach et al demonstrated that the in vivo application of CTLA-4–specific antibodies not only resulted in the rejection of preestablished tumors but also enhanced antitumor immunity after secondary tumor challenge. The fact that the tumor environment frequently expresses low levels of CD80/86 or even lacks these co-stimulatory proteins (reviewed in Seliger et al) indicated that additional mechanisms might account for the in vivo effects of anti-CTLA-4 antibodies (reviewed in Blank and Enk). In this regard, several groups could demonstrate that anti-CTLA-4 antibodies mediate Fcγ-receptor-dependent intratumoral depletion of Treg cells (the only cell type with constitutive surface expression of CTLA-4) resulting in increased intratumoral effector/regulatory T-cell ratios (Figure 4E).

Based on the preclinical results, two fully human mAbs with specificity for human CTLA-4 – tremelimumab and ipilimumab – have been generated and evaluated in patients with late-stage melanoma. While tremelimumab failed to significantly improve the survival rate of advanced melanoma patients, two ipilimumab Phase III trials showed significant improvement of overall survival. In 2013, ipilimumab was, therefore, approved by the European Commission as first-line treatment for adult patients with advanced melanoma. The difference in clinical efficacy of the two mAbs might be explained by the isotypes – IgG1 (ipilimumab) versus IgG2 (tremelimumab). Human IgG1 binds to Fcγ-receptors with higher affinity than human IgG2, which may allow a more efficient in vivo depletion of the CTLA-4–expressing Treg cells. In order to exploit possible synergies between blockade of CTLA-4 and programmed cell death protein-1 (PD-1) – a further checkpoint of T-cell activation – ipilimumab is currently tested in combination with nivolumab, a PD-1-blocking antibody.

### The power of CD28SAs

CD28SAs are a unique class of mAbs with a particularly strong signaling capacity, which is most likely related to their lateral binding mode to the CD28 homodimer, thereby allowing clustering by lattice formation (Figure 4F). CD28SAs apparently activate T-cells without the need for “signal one” provided by TCR-mediated antigen recognition. The complete loss of CD28SA responses in T-cell lines lacking TCR signaling, and in circulating human T-cells that
are deprived of cell contact-dependent “tonic” TCR signals that depend on cellular interactions in the tissues, indicates, however, that the ability of CD28SAs to polyclonally activate all CD28-expressing T-cells constitutes an extreme case of co-stimulation, where very strong CD28 signals amplify very weak TCR-derived signals to a level sufficient for T-cell activation. Indeed, the site of this amplification has been mapped to the SLP76/NAV1/ITK signalingosome (Figure 3).

In line with this conclusion, Treg cells, which, in contrast to all conventional T-cells not undergoing an immune response, are constantly stimulated by recognition of cognate (self-) antigen and hence display a higher level of phosphorylation in their TCR signal transduction machinery, and are activated by lower concentrations of CD28SAs than conventional T-cells (Figure 4F).

This preferential activation of Treg cells by CD28SAs has been successfully exploited in multiple rodent models of autoimmunity, inflammation, solid organ transplantation, and areactived by lower concentrations of CD28SAs than conventional T-cells (Figure 4F).

This finding was verified in vivo in a small T-cell subset. Furthermore, human peripheral blood mononuclear cells do not respond to soluble TGN1412 (now renamed TAB08) because, as mentioned above, they lack the pre-activation of the TCR signaling machinery that depends on cellular interactions in tissues but is lost in the circulation.

In the meantime, an assay was developed in which the response of circulating T-cells to CD28SAs is restored by resetting them to tissue-like conditions.

In this system, it was shown that just like in rodents, application of low CD28SA concentrations results in the selective activation of Treg cells (Figure 4F). This finding was verified in vivo in a new Phase I study employing very low doses of the drug, which led to the selective release of the Treg signature cytokine IL-10 into the circulation, and further clinical trials in RA patients have been initiated with encouraging results.

Concluding remarks

The central positioning of the CD28/CD80/86/CTLA-4 receptor–ligand system in the initiation and control of effector and Treg cell responses makes it an attractive target for therapeutic modulation of the immune system. Blockade of the shared ligands CD80/86 is now firmly established in RA management, with other applications still in the experimental phase. Selective blockade of CD28 co-stimulation without interfering with CTLA-4 ligation by using monovalent mAb derivatives is a promising alternative, which is in late preclinical development. Conversely, releasing only the “break” by blocking CTLA-4 has proven effective in boosting immune attack on cancer, with melanoma being at the most advanced stage in clinical use. Finally, the unique responsiveness of Treg cells to low-dose application of CD28SAs, which has proven effective in a vast array of immunopathologies in rodent models, has recovered from its setback during a catastrophic FIH trial, which now is recognized as due to unexpected overdosing. The next years will show whether as observed in those models, mobilization and recruitment of Treg cells will benefit patients with autoimmune and inflammatory disorders.

Acknowledgments

The authors like to thank the Deutsche Forschungsgemeinschaft (Research Unit 2123, SFB688, HU 295/12-1, BE 4080/2-1) and the Deutsche José Carreras Leukämie-Stiftung e.V. (R 13/25) for financial support.

Disclosure

TH is a consultant to TheraMAB LLC which develops clinical use of CD28SA. The other authors report no conflicts of interest in this work.

References


